Skip to main content
. 2024 Mar 13;15:2271. doi: 10.1038/s41467-024-46558-4

Fig. 1. Durable T cell immune response against HPV derived antigens of a long-term survived metastatic cervical cancer patient after MASCT treatment.

Fig. 1

a The schematic diagram of the therapy history for a patient with metastatic cervical cancer who had previously failed standard treatment and presented with bone metastasis on the right sacroiliac joint. After local irradiation, the patient repeatedly received eight courses of MASCT treatments in the following 6 years. Each course of treatment contains three injections for multiple antigen peptide-pulsed autologous mature DCs and three injections for peptide-pulsed mature DCs-induced autologous T cells. b Emission computed tomography (ECT) scanning images of the cervical cancer patient before and after MASCT treatment. c Ex vivo screening of immune responses against HPV antigen peptides of the HPV-positive cervical cancer patient treated with MASCT immunotherapy. IFNγ−ELISPOT was performed to detect specific immune responses against HPV16/18/58 peptides of the patient’s PBMCs. W/O without peptide, ENV irrelevant peptide control, NA not available. d Representative images of IFNγ ELISpot wells of the HPV18 E6/E7 immune responses at 15 months after MASCT immunotherapy. Data are shown as the mean ± SD, n = 3 technical replicates (c). Source data are provided as a Source Data file.